Dacarbazine
Alkylating Agent
DB00851
Approved Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
2
Targets
0
Resistance Mutations
0
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
The mechanism of action is not known, but appears to exert cytotoxic effects via its action as an alkylating agent. Other theories include DNA synthesis inhibition by its action as a purine analog, and interaction with SH groups. Dacarbazine is not cell cycle-phase specific.
Details
DrugBank ID
DB00851 ↗
Approval Date
1998-08-27
Molecular Weight
182.187 g/mol
Drug Class
Alkylating Agent
ATC Codes
L01AX04
Synonyms
Biocarbazine, Dacarbazin, Dacarbazina
PubChem
CID: 5351166 ↗
ChEMBL
CHEMBL476 ↗
SMILES
CN(C)\N=N\C1=C(N=CN1)C(N)=O
ADMET Profile
Computing properties…